ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

DRCCA Committee, ACCC, DeVita Reach Agreement On CCOP

October 16, 1981

New Phase III Trial Reviews Approve 25%; Should Trialists Worry? Not Yet,

January 19, 2007

Aranesp Improved Anemia In MDS In Phase II Trial

September 30, 2005

In Brief CCOP Prospects Submit 130 Letters Of Intent; DeVita recovering On Schedule from Surgery

September 26, 1986

Hatfield, Kennedy Bill would Establish Panel for Clinical Research

February 16, 1996

Klausner: “The More We Know About The Causes, The Better We Are at Prevention”

June 27, 1997